Literature DB >> 12470296

Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor gamma co-activator 1 alpha.

Hannes Oberkofler1, Elisabeth Schraml, Franz Krempler, Wolfgang Patsch.   

Abstract

Peroxisome-proliferator-activated receptor (PPAR) gamma co-activator 1 alpha (PGC-1 alpha/PPARGC1) plays an important role in energy metabolism by co-ordinating transcriptional programmes of mitochondrial biogenesis, adaptive thermogenesis and fatty acid beta-oxidation. PGC-1 alpha has also been identified to play a role in the intermediary metabolism by co-activating key transcription factors of hepatic gluconeogenesis and glucose uptake in muscles. In the present study, we show that PGC-1 alpha serves as a co-activator for the liver X receptor (LXR) alpha, known to contribute to the regulation of cellular cholesterol homoeostasis. In transient transfection studies, PGC-1 alpha amplified the LXR-mediated autoregulation of the LXR alpha promoter in a human brown adipocyte line and in 3T3-L1 cells via an LXR response element described previously. LXR-mediated transactivation via a natural LXR response element from the cholesteryl ester transfer-protein gene promoter was also enhanced by PGC-1 alpha in a ligand-dependent manner. Mutational analysis showed that the LXXLL signature motif (L2) of PGC-1 alpha was essential for co-activation of LXR-mediated transcriptional responses. This motif is located in the vicinity of the binding region for a putative repressor described previously. The repressor sequesters PGC-1 alpha from PPAR alpha and the glucocorticoid receptor, and this repressor did not interfere with PGC-1 alpha-mediated co-activation of LXR-dependent gene transcription. Moreover, inhibition of p38 mitogen-activated protein kinase signalling, shown to abolish the co-activation of PPAR alpha by PGC-1 alpha, had only a moderate inhibitory effect on the co-activation of LXR. These results identify PGC-1 alpha as a bona fide LXR co-activator and implicate distinct interfaces of PGC-1 alpha and/or additional cofactors in the modulation of LXR and PPAR alpha transcriptional activities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12470296      PMCID: PMC1223253          DOI: 10.1042/BJ20021665

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

1.  A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis.

Authors:  P Puigserver; Z Wu; C W Park; R Graves; M Wright; B M Spiegelman
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

2.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

3.  An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha.

Authors:  B A Janowski; P J Willy; T R Devi; J R Falck; D J Mangelsdorf
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

4.  OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor.

Authors:  M Teboul; E Enmark; Q Li; A C Wikström; M Pelto-Huikko; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

5.  Activation of PPARgamma coactivator-1 through transcription factor docking.

Authors:  P Puigserver; G Adelmant; Z Wu; M Fan; J Xu; B O'Malley; B M Spiegelman
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

6.  The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism.

Authors:  B M Forman; B Ruan; J Chen; G J Schroepfer; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

7.  Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha.

Authors:  Janice M Huss; Ryan P Kopp; Daniel P Kelly
Journal:  J Biol Chem       Date:  2002-08-13       Impact factor: 5.157

8.  Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres.

Authors:  Jiandie Lin; Hai Wu; Paul T Tarr; Chen-Yu Zhang; Zhidan Wu; Olivier Boss; Laura F Michael; Pere Puigserver; Eiji Isotani; Eric N Olson; Bradford B Lowell; Rhonda Bassel-Duby; Bruce M Spiegelman
Journal:  Nature       Date:  2002-08-15       Impact factor: 49.962

9.  LXR, a nuclear receptor that defines a distinct retinoid response pathway.

Authors:  P J Willy; K Umesono; E S Ong; R M Evans; R A Heyman; D J Mangelsdorf
Journal:  Genes Dev       Date:  1995-05-01       Impact factor: 11.361

10.  Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis.

Authors:  V Zilberfarb; F Piétri-Rouxel; R Jockers; S Krief; C Delouis; T Issad; A D Strosberg
Journal:  J Cell Sci       Date:  1997-04       Impact factor: 5.285

View more
  30 in total

1.  Modular evolution of PGC-1alpha in vertebrates.

Authors:  Christophe M R LeMoine; Stephen C Lougheed; Christopher D Moyes
Journal:  J Mol Evol       Date:  2010-05-05       Impact factor: 2.395

2.  Characterization of novel peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) isoform in human liver.

Authors:  Thomas K Felder; Selma M Soyal; Hannes Oberkofler; Penelope Hahne; Simon Auer; Richard Weiss; Gabriele Gadermaier; Karl Miller; Franz Krempler; Harald Esterbauer; Wolfgang Patsch
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

Review 3.  PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes.

Authors:  S Soyal; F Krempler; H Oberkofler; W Patsch
Journal:  Diabetologia       Date:  2006-05-17       Impact factor: 10.122

4.  Differential interactions of antiretroviral agents with LXR, ER and GR nuclear receptors: potential contributing factors to adverse events.

Authors:  J Svärd; F Blanco; D Nevin; D Fayne; F Mulcahy; M Hennessy; J P Spiers
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

5.  Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.

Authors:  Zhongmin Xiang; Marta Valenza; Libin Cui; Valerio Leoni; Hyun-Kyung Jeong; Elisa Brilli; Jiangyang Zhang; Qi Peng; Wenzhen Duan; Steven A Reeves; Elena Cattaneo; Dimitri Krainc
Journal:  J Neurosci       Date:  2011-06-29       Impact factor: 6.167

6.  SIRT1 is a transcriptional enhancer of the glucocorticoid receptor acting independently to its deacetylase activity.

Authors:  Shigeru Suzuki; James R Iben; Steven L Coon; Tomoshige Kino
Journal:  Mol Cell Endocrinol       Date:  2017-09-18       Impact factor: 4.102

7.  Restoration of sterol-regulatory-element-binding protein-1c gene expression in HepG2 cells by peroxisome-proliferator-activated receptor-gamma co-activator-1alpha.

Authors:  Hannes Oberkofler; Elisabeth Schraml; Franz Krempler; Wolfgang Patsch
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

8.  ApoE-/- PGC-1α-/- mice display reduced IL-18 levels and do not develop enhanced atherosclerosis.

Authors:  Sokrates Stein; Christine Lohmann; Christoph Handschin; Elin Stenfeldt; Jan Borén; Thomas F Lüscher; Christian M Matter
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

9.  Multiple binding modes between HNF4alpha and the LXXLL motifs of PGC-1alpha lead to full activation.

Authors:  Geun Bae Rha; Guangteng Wu; Steven E Shoelson; Young-In Chi
Journal:  J Biol Chem       Date:  2009-10-21       Impact factor: 5.157

10.  Cross-talk between oxysterols and glucocorticoids: differential regulation of secreted phopholipase A2 and impact on oligodendrocyte death.

Authors:  Amalia Trousson; Joelle Makoukji; Patrice X Petit; Sophie Bernard; Christian Slomianny; Michael Schumacher; Charbel Massaad
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.